Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer
The traditional immune checkpoint blockade therapy benefits some patients with cancer, but elicits no response in certain cancers, such as pancreatic adenocarcinoma (PAAD); thus, novel checkpoints and effective targets are required. Here, we found that there was a higher Neuropilin (NRP) expression...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-04, Vol.15 (8), p.2225 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 2225 |
| container_title | Cancers |
| container_volume | 15 |
| creator | He, Li-Hong Zhang, Xiao-Zhen Lao, Meng-Yi Zhang, Han-Jia Yang, Han-Shen Bai, Xue-Li |
| description | The traditional immune checkpoint blockade therapy benefits some patients with cancer, but elicits no response in certain cancers, such as pancreatic adenocarcinoma (PAAD); thus, novel checkpoints and effective targets are required. Here, we found that there was a higher Neuropilin (NRP) expression in tumor tissues as novel immune checkpoints, which was associated with poor prognosis and pessimistic responses to immune checkpoint blockade therapy. In the tumor microenvironment of PAAD samples, NRPs were widely expressed in tumor, immune and stromal cells. The relationship of NRPs with tumor immunological features in PAAD and pan-cancer was evaluated using bioinformatics methods; it was positively correlated with the infiltration of myeloid immune cells and the expression of most immune checkpoint genes. Bioinformatics analysis, in vitro and in vivo experiments suggested that NRPs exhibit potential immune-related and immune-independent pro-tumor effects. NRPs, especially NRP1, are attractive biomarkers and therapeutic targets for cancers, particularly PAAD. |
| doi_str_mv | 10.3390/cancers15082225 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10136637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A747308934</galeid><sourcerecordid>A747308934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-44b05f11f58a4f330615ec88ce4f00fc373b4c86a1f39cc42b2b2407ff44333e3</originalsourceid><addsrcrecordid>eNptksFPHCEUxompUbN67q0h6aWX1cfADMypsZtWTYztYXsmLPvYRWdgCjMm_vdlq7VqyjtAHr_vew_yCHnP4JTzFs6sCRZTZjWoqqrqPXJUgazmTdOKdy_Oh-Qk51soi3MmG3lADrlkLbBaHBF91fdTQLrYor0bog8jvcEpxcF3PmRqMr2J99jRLz72Jt2VctSENV1uMZkBp9FbujRpg2OmLib6o7SU0OzSiz_dHZN9Z7qMJ0_7jPz89nW5uJxff7-4Wpxfz60QfJwLsYLaMeZqZYTjHBpWo1XKonAAznLJV8KqxjDHW2tFtSohQDpX5Jwjn5HPj77DtOpxbTGMyXR6SL60_aCj8fr1TfBbvYn3mgHjTVP8Z-TTk0OKvybMo-59tth1JmCcsq4UE3XVgFIF_fgGvY1TCuV9hYKmBqgk_KM2pkPtg4ulsN2Z6nMpJAfVclGo0_9QJdbYexsDOl_yrwRnjwKbYs4J3fMjGejdXOg3c1EUH17-zTP_dwr4b5XLs6w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2806500270</pqid></control><display><type>article</type><title>Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>He, Li-Hong ; Zhang, Xiao-Zhen ; Lao, Meng-Yi ; Zhang, Han-Jia ; Yang, Han-Shen ; Bai, Xue-Li</creator><creatorcontrib>He, Li-Hong ; Zhang, Xiao-Zhen ; Lao, Meng-Yi ; Zhang, Han-Jia ; Yang, Han-Shen ; Bai, Xue-Li</creatorcontrib><description>The traditional immune checkpoint blockade therapy benefits some patients with cancer, but elicits no response in certain cancers, such as pancreatic adenocarcinoma (PAAD); thus, novel checkpoints and effective targets are required. Here, we found that there was a higher Neuropilin (NRP) expression in tumor tissues as novel immune checkpoints, which was associated with poor prognosis and pessimistic responses to immune checkpoint blockade therapy. In the tumor microenvironment of PAAD samples, NRPs were widely expressed in tumor, immune and stromal cells. The relationship of NRPs with tumor immunological features in PAAD and pan-cancer was evaluated using bioinformatics methods; it was positively correlated with the infiltration of myeloid immune cells and the expression of most immune checkpoint genes. Bioinformatics analysis, in vitro and in vivo experiments suggested that NRPs exhibit potential immune-related and immune-independent pro-tumor effects. NRPs, especially NRP1, are attractive biomarkers and therapeutic targets for cancers, particularly PAAD.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15082225</identifier><identifier>PMID: 37190154</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenocarcinoma ; Algorithms ; Antibodies ; Bioinformatics ; Biological markers ; Biomarkers ; Development and progression ; Drug therapy ; Experiments ; Genes ; Genomes ; Glycoproteins ; Health aspects ; Immune checkpoint inhibitors ; Immunology ; Immunoregulation ; Immunotherapy ; Kinases ; Medical prognosis ; Metastases ; Neuropilin ; Ontology ; Pancreatic cancer ; Software ; Statistical analysis ; Stromal cells ; Therapeutic applications ; Therapeutic targets ; Tumor microenvironment ; Tumors</subject><ispartof>Cancers, 2023-04, Vol.15 (8), p.2225</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c443t-44b05f11f58a4f330615ec88ce4f00fc373b4c86a1f39cc42b2b2407ff44333e3</cites><orcidid>0000-0002-2694-2974 ; 0000-0002-2934-0880</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136637/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136637/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37190154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Li-Hong</creatorcontrib><creatorcontrib>Zhang, Xiao-Zhen</creatorcontrib><creatorcontrib>Lao, Meng-Yi</creatorcontrib><creatorcontrib>Zhang, Han-Jia</creatorcontrib><creatorcontrib>Yang, Han-Shen</creatorcontrib><creatorcontrib>Bai, Xue-Li</creatorcontrib><title>Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>The traditional immune checkpoint blockade therapy benefits some patients with cancer, but elicits no response in certain cancers, such as pancreatic adenocarcinoma (PAAD); thus, novel checkpoints and effective targets are required. Here, we found that there was a higher Neuropilin (NRP) expression in tumor tissues as novel immune checkpoints, which was associated with poor prognosis and pessimistic responses to immune checkpoint blockade therapy. In the tumor microenvironment of PAAD samples, NRPs were widely expressed in tumor, immune and stromal cells. The relationship of NRPs with tumor immunological features in PAAD and pan-cancer was evaluated using bioinformatics methods; it was positively correlated with the infiltration of myeloid immune cells and the expression of most immune checkpoint genes. Bioinformatics analysis, in vitro and in vivo experiments suggested that NRPs exhibit potential immune-related and immune-independent pro-tumor effects. NRPs, especially NRP1, are attractive biomarkers and therapeutic targets for cancers, particularly PAAD.</description><subject>Adenocarcinoma</subject><subject>Algorithms</subject><subject>Antibodies</subject><subject>Bioinformatics</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Experiments</subject><subject>Genes</subject><subject>Genomes</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunology</subject><subject>Immunoregulation</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Neuropilin</subject><subject>Ontology</subject><subject>Pancreatic cancer</subject><subject>Software</subject><subject>Statistical analysis</subject><subject>Stromal cells</subject><subject>Therapeutic applications</subject><subject>Therapeutic targets</subject><subject>Tumor microenvironment</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptksFPHCEUxompUbN67q0h6aWX1cfADMypsZtWTYztYXsmLPvYRWdgCjMm_vdlq7VqyjtAHr_vew_yCHnP4JTzFs6sCRZTZjWoqqrqPXJUgazmTdOKdy_Oh-Qk51soi3MmG3lADrlkLbBaHBF91fdTQLrYor0bog8jvcEpxcF3PmRqMr2J99jRLz72Jt2VctSENV1uMZkBp9FbujRpg2OmLib6o7SU0OzSiz_dHZN9Z7qMJ0_7jPz89nW5uJxff7-4Wpxfz60QfJwLsYLaMeZqZYTjHBpWo1XKonAAznLJV8KqxjDHW2tFtSohQDpX5Jwjn5HPj77DtOpxbTGMyXR6SL60_aCj8fr1TfBbvYn3mgHjTVP8Z-TTk0OKvybMo-59tth1JmCcsq4UE3XVgFIF_fgGvY1TCuV9hYKmBqgk_KM2pkPtg4ulsN2Z6nMpJAfVclGo0_9QJdbYexsDOl_yrwRnjwKbYs4J3fMjGejdXOg3c1EUH17-zTP_dwr4b5XLs6w</recordid><startdate>20230410</startdate><enddate>20230410</enddate><creator>He, Li-Hong</creator><creator>Zhang, Xiao-Zhen</creator><creator>Lao, Meng-Yi</creator><creator>Zhang, Han-Jia</creator><creator>Yang, Han-Shen</creator><creator>Bai, Xue-Li</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2694-2974</orcidid><orcidid>https://orcid.org/0000-0002-2934-0880</orcidid></search><sort><creationdate>20230410</creationdate><title>Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer</title><author>He, Li-Hong ; Zhang, Xiao-Zhen ; Lao, Meng-Yi ; Zhang, Han-Jia ; Yang, Han-Shen ; Bai, Xue-Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-44b05f11f58a4f330615ec88ce4f00fc373b4c86a1f39cc42b2b2407ff44333e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma</topic><topic>Algorithms</topic><topic>Antibodies</topic><topic>Bioinformatics</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Experiments</topic><topic>Genes</topic><topic>Genomes</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunology</topic><topic>Immunoregulation</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Neuropilin</topic><topic>Ontology</topic><topic>Pancreatic cancer</topic><topic>Software</topic><topic>Statistical analysis</topic><topic>Stromal cells</topic><topic>Therapeutic applications</topic><topic>Therapeutic targets</topic><topic>Tumor microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Li-Hong</creatorcontrib><creatorcontrib>Zhang, Xiao-Zhen</creatorcontrib><creatorcontrib>Lao, Meng-Yi</creatorcontrib><creatorcontrib>Zhang, Han-Jia</creatorcontrib><creatorcontrib>Yang, Han-Shen</creatorcontrib><creatorcontrib>Bai, Xue-Li</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Li-Hong</au><au>Zhang, Xiao-Zhen</au><au>Lao, Meng-Yi</au><au>Zhang, Han-Jia</au><au>Yang, Han-Shen</au><au>Bai, Xue-Li</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-04-10</date><risdate>2023</risdate><volume>15</volume><issue>8</issue><spage>2225</spage><pages>2225-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The traditional immune checkpoint blockade therapy benefits some patients with cancer, but elicits no response in certain cancers, such as pancreatic adenocarcinoma (PAAD); thus, novel checkpoints and effective targets are required. Here, we found that there was a higher Neuropilin (NRP) expression in tumor tissues as novel immune checkpoints, which was associated with poor prognosis and pessimistic responses to immune checkpoint blockade therapy. In the tumor microenvironment of PAAD samples, NRPs were widely expressed in tumor, immune and stromal cells. The relationship of NRPs with tumor immunological features in PAAD and pan-cancer was evaluated using bioinformatics methods; it was positively correlated with the infiltration of myeloid immune cells and the expression of most immune checkpoint genes. Bioinformatics analysis, in vitro and in vivo experiments suggested that NRPs exhibit potential immune-related and immune-independent pro-tumor effects. NRPs, especially NRP1, are attractive biomarkers and therapeutic targets for cancers, particularly PAAD.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37190154</pmid><doi>10.3390/cancers15082225</doi><orcidid>https://orcid.org/0000-0002-2694-2974</orcidid><orcidid>https://orcid.org/0000-0002-2934-0880</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-04, Vol.15 (8), p.2225 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10136637 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Adenocarcinoma Algorithms Antibodies Bioinformatics Biological markers Biomarkers Development and progression Drug therapy Experiments Genes Genomes Glycoproteins Health aspects Immune checkpoint inhibitors Immunology Immunoregulation Immunotherapy Kinases Medical prognosis Metastases Neuropilin Ontology Pancreatic cancer Software Statistical analysis Stromal cells Therapeutic applications Therapeutic targets Tumor microenvironment Tumors |
| title | Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T07%3A41%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20Checkpoint%20Neuropilins%20as%20Novel%20Biomarkers%20and%20Therapeutic%20Targets%20for%20Pancreatic%20Cancer&rft.jtitle=Cancers&rft.au=He,%20Li-Hong&rft.date=2023-04-10&rft.volume=15&rft.issue=8&rft.spage=2225&rft.pages=2225-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15082225&rft_dat=%3Cgale_pubme%3EA747308934%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2806500270&rft_id=info:pmid/37190154&rft_galeid=A747308934&rfr_iscdi=true |